Search Results - Roger Bitrán

  • Showing 1 - 5 results of 5
Refine Results
  1. 1
    How the COVID-19 pandemic affects specialty training: An analysis of a nationwide survey among otolaryngology residents in Chile

    How the COVID-19 pandemic affects specialty training: An analysis of a nationwide survey among otolaryngology residents in Chile by Álvarez, Matías L, Waissbluth, Sofia, González, Claudia, Napolitano, Carla, Torrente, Mariela, Délano, Paul H, Alarcón, Ricardo, Fernández, Francisca, Bitrán, Roger

    Published in Medwave
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    How the COVID-19 pandemic affects specialty training: An analysis of a nationwide survey among otolaryngology residents in C

    How the COVID-19 pandemic affects specialty training: An analysis of a nationwide survey among otolaryngology residents in C by Matías L Álvarez, Sofia Waissbluth, Claudia González, Carla Napolitano, Mariela Torrente, Paul H Délano, Ricardo Alarcón, Francisca Fernández, Roger Bitrán

    Published in Medwave
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Perfil de consulta ambulatoria otorrinolaringológica en pandemia por COVID-19

    Perfil de consulta ambulatoria otorrinolaringológica en pandemia por COVID-19 by Godoy A., Jorge, Bitrán P., Roger, Lamas A., Francisca, Sáez B., Fabián, Pizarro B., Rodrigo, Lancelloti G., Domingo, Ortúzar G., Esteban

    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Perfil de consulta ambulatoria otorrinolaringológica en pandemia por COVID-19

    Perfil de consulta ambulatoria otorrinolaringológica en pandemia por COVID-19 by Godoy A., Jorge, Bitrán P., Roger, Lamas A., Francisca, Sáez B., Fabián, Pizarro B., Rodrigo, Lancelloti G., Domingo, Ortúzar G., Esteban

    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

    Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial by Mateos, Maria-Victoria, Blacklock, Hilary, Schjesvold, Fredrik Hellem, Oriol, Albert, Simpson, David, George, Anupkumar, Goldschmidt, Hartmut, Larocca, Alessandra, Chanan-Khan, Asher, Sherbenou, Daniel, Avivi, Irit, Benyamini, Noam, Iida, Shinsuke, Matsumoto, Morio, Suzuki, Kenshi, Ribrag, Vincent, Usmani, Saad Z, Jagannath, Sundar, Ocio, Enrique M, Rodriguez-Otero, Paula, San Miguel, Jesus, Kher, Uma, Farooqui, Mohammed, Liao, Jason, Marinello, Patricia, Lonial, Sagar

    Request full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: